-
Mashup Score: 1Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial - 1 year(s) ago
There is limited published information on outcome adjudication in heart failure (HF).The authors sought to compare investigator reports (IRs) to a Cli…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial - Nature Medicine - 2 year(s) ago
The potential of all-virtual clinical trials in cardiology is shown by the CHIEF-HF trial, conducted in the midst of the COVID-19 pandemic, which found that an SGLT2 inhibitor can alleviate heart failure symptoms in patients irrespective of ejection fraction or diabetes status.
Source: NatureCategories: Cardiologists, Latest HeadlinesTweet-
🔥#CHIEF_HF Another proof of significant improvement of #QoL & #KCCQ in #HF , especially in #HFpEF (60% of the enrolled pop.) Confirming the results of #DAPA_HF #EMPEROR_Reduced & #EMPEROR_Preserved @JavedButler1 @DLBHATTMD @JavedButler1 @nephondemand https://t.co/2CpAh3bPoZ https://t.co/rgsGrZDLqD
-
-
Mashup Score: 1
Empagliflozin reduced serious heart failure outcomes across doses and combinations of disease-modifying therapies for HFrEF. Clinically, these data suggest that empagliflozin might be considered as a foundational therapy in patients with HFrEF regardless of their existing background therapy.
Categories: Cardiologists, Latest HeadlinesTweet-
#SGLT2i #Empagliflozin provides CV benefits whatever are the background therapies in #EMPEROR_Reduced #HF https://t.co/k549Xxphvm
-
-
Mashup Score: 3
Empagliflozin reduced serious heart failure outcomes across doses and combinations of disease-modifying therapies for HFrEF. Clinically, these data suggest that empagliflozin might be considered as a foundational therapy in patients with HFrEF regardless of their existing background therapy.
Categories: Cardiologists, Latest HeadlinesTweet-
Empagliflozin, background therapies #therapeutic_combinations #EMPEROR_Reduced: post-hoc analysis. https://t.co/5JTWIO5B14
-
-
Mashup Score: 15
AbstractAims. We evaluated the influence of sacubitril/valsartan on the effects of sodium-glucose cotransporter 2 (SGLT2) inhibition with empagliflozin in patie
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#EMPEROR_Reduced influence of #ARNI on efficacy & safety in #HFrEF Before or After : it doesn’t change anything. My choice: together Let’s see new #GDLs at #HeartFailure2021 @HFA_President @KTamirisaMD @ShelleyZieroth @DrNasrien @MicheleSenni @DLBHATTMD https://t.co/WBSvGt07Hf https://t.co/IXPapre8vT
-
-
Mashup Score: 3Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction - 3 year(s) ago
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but a
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet-
☝️#EMPEROR_Reduced Empaglifozin impact on Clinical Stability in #HFrEF @CircAHA @DrDEliaEmilia @carlosguizars @iamritu @MicheleSenni @gcfmd @gbiondizoccai @EkateriniL @AspriAlexia @FrancescoPaneniandreas @Dr_Manito @JavierdeJuan1 @JGrapsa @Filippatos https://t.co/hLfwqMfuCJ https://t.co/9e1Jd7ivrt
-
-
Mashup Score: 9Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction - 3 year(s) ago
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but a
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet-
#EMPEROR_Reduced Effect on Clinical Stability in #HFrEF Multiple advantages of #SGLT2i 🔥 @DrMarthaGulati @MaasAngela @DLBHATTMD @SABOURETCardio @ShelleyZieroth @DBelardoMD @HeartOTXHeartMD @JJheart_doc @DrNasrien @mvaduganathan @mmamas1973 @rahatheart1 https://t.co/hLfwqMfuCJ https://t.co/M6kHjbksVx
-
-
Mashup Score: 4Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function - 3 year(s) ago
Background: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction), empagliflozin reduced cardiovascular death or heart failure (HF) ho
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet-
#EMPEROR_Reduced Cardiac & Kidney benefit of Empaglifozin in #HF across the spectrum of #Kidney function @CircAHA @FaiezZANNAD @JavedButler1 @DLBHATTMD @DrMarthaGulati @SABOURETCardio @mmamas1973 @ValleAlfonso @ShelleyZieroth @AnastasiaSMihai @DBelardoMD https://t.co/cU0wl0QxlV https://t.co/yaca4nmFhB
-
-
Mashup Score: 7ESC 2020 Discussion: The EMPEROR-Reduced Study — Dr Milton Packer & Dr Harriette Van Spall | RadcliffeCardiology - 4 year(s) ago
RadcliffeCardiology article video ESC 2020 Discussion: The EMPEROR-Reduced Study — Dr Milton Packer & Dr Harriette Van Spall
Source: www.radcliffecardiology.comCategories: Cardiologists, Latest HeadlinesTweet-
20 min masterclass on the history of #SGLT2i RCTs, key diffs between #EMPEROR_REDUCED & #DAPAHF, how risk profile of patients may affect study outcomes, drug vs class effects & more w/ Dr Milton Packer🌟 #heartfailure #ESCCongress https://t.co/8FZNLov52W https://t.co/qbxWamvzUg https://t.co/yyQTD64mrE https://t.co/xcmcLVB6KB
-
-
Mashup Score: 13European Society of Cardiology - Sign in - 4 year(s) ago
Help us give you the best experience possible – sign in here if you have a My ESC account already No account? No problem – create one below – it takes just a few minutes Email PasswordForgot password? …
Source: idp.escardio.orgCategories: Cardiologists, Latest HeadlinesTweet-
#ESCCongress Results of #EMPEROR_REDUCED RCT announced! 🔹Relative to placebo, #Empagliflozin ⬇️primary composite outcome of #CVdeath or #HFhospitalization among patients with #HFrEF by 25%, p<0.001. 🔹Significant reductions in secondary endpoints noted https://t.co/cKHqSM0iOv https://t.co/1NIWbCCjI5 https://t.co/BFjjcnMomX
-
🔥#EMPEROR_Reduced Comparison of investigator vs CEC teported #HF_Outcomes 👉 ⬆️ agreement between CEC &. Investigators vs Algorithm identified 👉 Need for a broader definition of. #HHF including “for or with” @JACCJournals @BiykemB @JavedButler1 @gcfmd https://t.co/YRrIqwSrwp https://t.co/c68Qmic3oP